115 Diagnostic and management of patients with heart failure with preserved systolic function in hospital settings: a French observational cohort survey

Abstract

Few data are available about real life and management of patients heart failure with preserved systolic function (HF-PSF). To describe patients, disease characteristics and treatment strategies implemented in HF-PSF patients hospitalized for confirmed acute HF with LVEF≥45%. An observational study was conducted in 68 hospital in France with 2 steps: (1) a registry part in patients hospitalized for confirmed acute HF for estimation of proportion of HF-PSF patients in the overall HF patients. (2) a detailed part with data collection of patients recently diagnosed for HF-PSF (LVEF ≥ 45% evaluated within 8 days following hospitalization date). 707 HF patients were enrolled in the registry with a proportion of 51% with HF-PSF. In detailed part 364 HF-PSF patients were selected, with a mean age of 79 years, 59%female, and a mean BMI 27.7kg/m. Main cardiovascular characteristics of HF-PSF patients were: atrial fibrillation (51%), coronary heart disease (32%), peripheral arterial disease (15%) and stroke (13%) as CV antecedents and hypertension (78%), obesity (45.5%) and diabetes (29%) as risk factors. Mean values were: blood pressure 133/86mmHg, HR 92beats/min, creatinine 13.8mg/l, haemoglobin 12.0g/dl. BNP was performed in 243 patients with a median value of 684 pg/ml and Nt-pro-BNP in 77 patients with a median value of 3999 pg/ml. Mean ejection fraction was 58±8%. Non CV co-morbidities were: renal failure(39%), COPD(20%), walking disorders (22%), depression(12%),cognitive disorders(8%)and cancers(5%). Treatment at discharge included: diur. (85%), ACE-i(57%), βB (56%), Ca antag (27%), ARB (20%), aldosterone blockers (13%), digoxin (16%), anticoagulants (52%), statins (48%), aspirin (32%) and amiodarone (28.5%). Much is not known about the epidemiology and management of HF-FSP in France but our study try to improve the knowledge on this disease with real life data even if until today there is no specific treatment.